Skip to content

Clinical Efficacy and Transcriptomics Study of Dachengqi Decoction in the Treatment of Sepsis-Induced Acute Gastrointestinal Injury

Clinical Efficacy and Transcriptomics Study of Dachengqi Decoction in the Treatment of Sepsis-Induced Acute Gastrointestinal Injury

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ITMCTR
Registry ID
ITMCTR2026000818
Enrollment
Unknown
Registered
2026-03-30
Start date
2024-09-03
Completion date
Unknown
Last updated
2026-04-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute gastrointestinal injury in sepsis

Interventions

Observation group:Dachengqi Decoction combined with conventional Western medical treatment

Sponsors

Hefei Third People's Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
19 Years to 95 Years

Inclusion criteria

Inclusion criteria: 1) Meets diagnostic criteria for sepsis and II-III grade SAGI; 2) Age 18 years; 3) Chinese medical pattern identification: Gastrointestinal Heat Stagnation Syndrome. Primary symptoms: high fever with shortness of breath, abdominal distension and (bloating), hard stools, inability to pass gas. Secondary symptoms: restlessness, delirious speech or even (delirium), halitosis, thirst, sweating of palms and soles, dark yellow urine. Tongue and pulse: red tongue with yellow and dry coating, deep-string or fine-rapid pulse.

Exclusion criteria

Exclusion criteria: 1. Age less than 18 years old; 2. Hospitalization duration less than 7 days; 3. Women in pregnancy or lactation; 4. Patients with malignant tumors, severe liver disease, hematological disorders, or immunodeficiency diseases; 5. Allergic to any component of Dachengqi Decoction; 6. Use of gastrointestinal motility drugs within the past two weeks; 7. Incomplete clinical data.

Design outcomes

Primary

MeasureTime frame
Intra-abdominal pressure;Gastrointestinal Function Scoring;Efficient;28-day mortality rate;Intestinal Wall Tissue Pathology Scoring;Citrulline, D-lactic acid, and inflammatory factors;

Secondary

MeasureTime frame
Intraperitoneal infusion pressure;Enteral nutrition tolerance;First bowel movement time;Mechanical Ventilation Duration;Hospitalization Duration;Procalcitonin (PCT), Interleukin-6 (IL-6), C-reactive protein (CRP);Acute Physiology and Chronic Health Evaluation;Intestinal wall blood flow;

Countries

China

Contacts

Public ContactWu Daorong

Hefei Third People's Hospital

wudaorong2009@163.com13721077658

Outcome results

None listed

Source: ITMCTR (via WHO ICTRP) · Data processed: May 1, 2026